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Abstract
Ufd2a is an E3 enzyme that adds ubiquitin to proteins that will then be sent to a
proteosome to be degraded. Previous experiments have shown an interaction between
Ufd2aI (in yeast and mouse) and the ubiquitous AAATPase, p97/VCP, which binds to
ubiquitylated proteins and has many essential functions in the cell which range from
mitosis to autophagy. Mutations in the p97/VCP gene resulting in amino acid
substitutions R155H or A232E are present in cases of Paget’s disease of the Bone with
Frontotemporal Dementia (IBMPFD), a type of inclusion body myopathy which presents
with an accumulation of autophagosomes. Using quantitative reporter systems we
developed for the Yeast 2-Hybrid assay we have found that Ufd2aI has the strongest
affinity for p97/VCP A232E, while its weakest interaction is with wild type p97/VCP.
Since p97/VCP is known to bind to a number of diverse molecules in a mutually
exclusive manner, we speculate that a stronger interaction between Ufd2aI and mutant
p97/VCP may inhibit other interactions essential to its function in resolving ubiquitylated
protein loaded autophagosomes.

5

Introduction
Ufd2a Isoforms
Ufd2a is a protein that is part of the ubiquitin-proteosome pathway. It is an E3
enzyme that adds ubiquitin to proteins that will then be sent to a proteosome to be
degraded (Kogel 199, Kaneko 29003, Mahoney 2002,). There are three different splice
forms of Ufd2a that are found only in muscle cells. Ufd2a is the shortest isoform of the
protein and it includes exons one though six and eight through twenty-seven. It is
expressed in most dividing cells of mammals and in precursor muscle cells called
myoblasts. Ufd2aII is the second largest isoform which consists of exons one through six,
seven, and eight through twenty-seven. This form of Ufd2a appears to be exclusively
expressed during the differentiation of myoblast cells. The third form, Ufd2aIII, consists
of all exons contained in Ufd2aII as well as the newly discovered exon 7a. This form of
the protein is only expressed in later stages of muscle differentiation and in mature,
striated, multinucleated muscle cells.

Yeast 2 Hybrid System
The identification of novel protein-protein interactions (PPIs) can help to discover
proteins that are part of the same cellular pathway. For example if one protein is known
to play a role in the regulation of cell division, and a second protein was discovered to
interact with it, then it could be hypothesized that the two are involved in the same
process. Therefore, when a novel interaction is found, new hypotheses can be generated
about the function of interacting protein pair. The Yeast 2 Hybrid (Y2H) is one method
by which to identify novel interactions between proteins in cells. This technique was
developed using the knowledge of the yeast Gal4 transcription factor and promoter
region. It was discovered that the DNA-binding domain and the activation domain of the
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Gal4 transcription factor could be expressed as two separate proteins and still induce
transcription of any gene placed downstream of the Gal4 promoter as long as the two
domains were brought into close proximity. Therefore, when one protein, referred to as
the bait, is fused to the DNA-binding domain and a second, referred to as the prey, is
fused to the activation domain, transcription of the gene downstream of the Gal4
promoter will occur if the bait and prey interact.
In a version of the Y2H system developed by Invitrogen, there are two pDEST
vectors that the bait and prey genes of interest are inserted into. They either contain the
DNA Binding Domain (DBD; pDEST32) or the Activation Domain (AD; pDEST22) of
the Gal4 transcription factor coded for upstream of where the genes of interest are
inserted, such that the final proteins will be fusion products.
These two vectors are first made in bacteria, they each also encode an antibiotic
resistance gene so that when in bacteria they are able to be selected for using that
antibiotic resistance gene. Once the vectors have been authenticated (by sequencing),
they are transformed into yeast where the two fusion proteins will be expressed. The
vectors also contain either a leucine synthase gene or a tryptophan synthase gene which
allow for selection of yeast that have both vectors when grown on plates lacking these
two amino acids.

Reporter System of Yeast 2 Hybrid System
The particular strain of yeast used in this Y2H system, MaV203 has been
engineered such that several reporter genes which include the histidine synthase HIS3 and
lacZ gene, are placed downstream of a Gal4 promoter; this allows an interaction to be
detected depending on either the type of media the yeast are grown on or through a
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β-galactosidase assay performed on the yeast cells.
Detection of transcription of the histidine synthase is through growth on a –his/–
leu/–trp plate containing different concentrations of 3-amino-1,2,4-triazole (3AT) which
is a histidine antagonist. The stronger the interaction of the bait and prey, the more
histindine synthase produced by the yeast, allowing them to survive on higher
concentrations of 3AT. This gives you a qualitative estimate of the strength of the
interaction. Detection of transcription of the lacZ gene is done by incubating the cells
with a substrate which forms a blue precipitate inside the yeast cells when cleaved by βgalactosidase, the enzyme product of the LacZ gene. The rate and intensity of color
development provide an estimate of the strength of the interaction. Combining the results
from these two assay systems allows verification of the interaction and eliminates false
positives.

VCP/p97 and Inclusion Body Myopathy associated with Paget’s disease of the Bone
and Frontotemperal Dementia (IBMPFD)
Previous experiments have shown that there is an interaction between Ufd2aI (in
yeast and mouse) and VCP/p97. It is part of the AAAtpase family of proteins.VCP/p97
binds to ubiquitilated proteins and has many essential functions which range from mitosis
to autophagy. Mutations in the p97/VCP gene resulting in amino acid substitutions
R155H or A232E are present in cases of Paget’s disease of the Bone with Frontotemporal
Dementia (IBMPFD), a type of inclusion body myopathy which presents with an
accumulation of autophagosomes (Ju and Weihl, 2010). There is some evidence that the
VCP/p97 R155H and VCP/p97 A232E interact with Ufd2aI (UI) in mouse and human
cells (Paul Taylor, personal communication).
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Through histidine synthase assays and β-Galactosidase assays in the Yeast 2
Hybrid system it was found there was no binding between Ufd2aIII and VCP/p97.
However there was significant binding between Ufd2a and VCP/p97. This led us to
question whether the binding affinity for mutations in VCP/p97 that is involved in the
autosomal dominant disease Inclusion Body Myopathy in association with Paget’s
disease of the Bone and Frontotemperal Dementia. It was found that there was a
significant difference in the binding between VCP/p97 Wild Type, R155H, and A232E.

Materials and Methods:
Cloning of Ufd2a and Ufd2aIII, VCP/p97 (WT, R155H, and A232E)
LR Clonase II Reaction
The Invitrogen Gateway system was used to clone Ufd2a into a p-DEST vector.
The Invitrogen system takes a plasmid that is specially modified for use in the Yeast 2
Hybrid system (Y2H). The plasmid has a ccdB death gene in between att sites. The
purpose of this system allows you to easily switch out the death gene with Ufd2a by a LR
Clonase II reaction. 150 ng of the entry clone (Ufd2a) which is in an entry vector
pDONR (from Bio 533 Spring 2010) which must be between 1-7 µl, 150 ng of
destination vector pDEST32 for Ufd2a and Ufd2aIII and pDest22 for VCP/p97 and
mutants, add TE Buffer until 8 µl pH 8.0 was added to a 1.5 ml microcentrifuge tube. The
LR clonase mixture was thawed on ice for two minutes and mix by shaking for
approximately 2 seconds, twice. To each sample add 2 µl of LR clonase mixture. This
was then mixed briefly. The reaction was incubated at 25oC for 1 hour. 1 µl of proteinase
K solution was added to complete reaction. Mix briefly again. This mixture was then
incubate at 37oC for ten minutes.
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Heat Shock Transformation
40 µl of DH5α max cells (E. coli) (Invitrogen) were thawed on ice in a 1.5 ml
microcentrifuge tube. 1 µl of LR reaction was pipietted into tube of cells and waited 15
minutes. Cells were placed in a 42oC water bath for 45 seconds. Immediately the tube
was placed on ice for 2 minutes. 100 µl of SoC media was added and flick tube to mix.
Tube was placed in shaker (approximately 200rpm) for 1 hour at 37oC. Tube was
removed from shaker and entire contents were spread on LB-antibiotic plate (gentamicin
for pDEST32 and ampicillin for pDEST22) and incubated overnight at 37oC.

Liquid Cultures for Miniprep Kit
3 ml of sterile Luria broth (LB) media was added to a 15 ml test tube. Gentamicin
or ampicillin was added to media depending which vector being used ( 5000x stock of
gentamicin is 50 mg/ml, so to a 3 ml culture 0.6 µl of gen is added, 1000x stock of
ampicillin is 30 mg/ml so 3 µl is added to a 3 ml culture). With a sterile pipette tip, touch
a colony and place the tip into a tube. Tube was placed in shaker overnight at 37oC

Miniprep Kit
Using the Bench Protocol of the QIAprep Spin Miniprep Kit, samples were
centrifuged in a 1.5 ml microcentrifuge tube. Use all 3 ml, this will have to be divided
into two 1.5 ml aliquots. Use same tube a second time. The pellet was resuspended in 250
µl of Buffer P1. 250 µl of Buffer P2 was added and mixed by inversion. Solution should
turn blue (if using LyseBlue). 350 µl of Buffer N3 was added and mixed by inversion.
Solution should turn colorless (if using LyseBlue). Solution was centrifuged for 10
minutes at 13000 rpm. The supernatant was applied to QIAprep spin column by pipetting.
Spin column was centrifuged for 60 seconds. Flow through was discarded. 500 µl Buffer
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PB was added to wash the column. Again the column was centrifuged for 60 seconds.
Flow through was discarded. The spin column was washed again with 750 µl Buffer PE.
Column was centrifuged for 60 seconds. Flow through was discarded and spun again for
60 seconds. Spin column was placed in a clean 1.5 ml microcentrifuge tube and 50 µl
Buffer EB was added to elute the protein, elution buffer was allowed to sit 60 seconds
and centrifuged for 1 minute. Determined the concentration of the sample using a
Nanodrop spectrophotometer.

Restriction Digest (using PvuII)
Restriction digests were performed to ensure the proper sequence of the Ufd2a
(VCP/p97 and mutants were in destination vectors and verified as the proper sequences,
Bio 533 spring 2010 class). 2 µl of Buffer 2 (10x stock), 1 µl PvuII enzyme (both from
NE biolabs), 250-500 ng of DNA (can be less if concentration is low), and dH2O until 20
µl was added to microcentrifuge tube. Mixture was incubated at 37oC for 2 hours. Tubes
were taken out of incubation, 4 µl 6x DNA was added. Prepare a 0.8% agarose gel adding
ethidium bromide. Samples were added to wells (include 1kb+ ladder). Run gel at 100
volts for 25-35 minutes. Gel was then visualized with UV light. The expected band
patters should be at 927, 1092, 1689, 4120, and 6151 base pairs.

Restriction Digest (using BamHI and NcoI)
Used same protocol as above except use Buffer 3 (NE biolabs) and 0.5 µl of each
restriction enzyme. The expected band pattern is 1423, 4614, and 7942 base pairs.

Site Directed Mutagenesis of Ufd2aIII
Using the LR Clonase II reaction did not work with Ufd2aIII. Therefore site directed
mutagenesis was used instead. Ufd2aIII was in a different vector (pDEST201; obtained
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from Brenda Cordiero). This vector did not have a stop codon and when put into the
pDEST32 vector it would not be in the correct reading frame. Therefore to correct that
problem site directed mutagenesis used. Using the QuikChange Lightning Enzyme
(Agilent) for Mutant Strand Synthesis Reaction prepared in a PCR tube 5 µl 10x reaction
buffer, 25 ng of DNA, 125g ng stop codon primer forward, 125 ng stop codon primer
reverse, 1 µl dNTP mix, 1.5 µl QuikSolution reagent, dH2O to a final volume of 50 µl.
1 µl QuikChange Lightning Enzyme was then added and put into PCR machine. Follow
chart temperatures and times. When stop codon was added there was a particular
restriction enzyme that cleaved the stop codon site (BfaI) using this enzyme as previously
stated in restriction enzyme section using 1 µl of BfaI and Buffer 4 (NE biolabs) the
sequence was confirmed by the banding pattern. Using the same protocol with different
primers (these primers added a nucleotide to shift the reading frame) the procedure was
carried out a second time. There was no convenient enzyme that would cleave the new
frame shift so the reaction was sent to the Genome Sequencing Center at The University
of Rhode Island.

Segment
1

2

Cycles
1

o

18
3

Temperature
o
95 C
o
95 C
o
60 C

1

68 C
o
68 C

Time
2 min
20 sec
10 sec
30
sec/kb
plasmid
length
5 min
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Sequencing of Ufd2a, Ufd2aIII, VCP/p97 and Mutants
Colonies that had the correct banding pattern with the restriction enzymes were
sent to the Genome Sequencing Center at the University of Rhode Island to confirm the
correct sequence of each protein.

Transformation into Yeast Cells
Preparation of Competent Cells
The S.c EasyComp Transformation Kit (Invitrogen) was used when 10 ml of YPD
media was inoculated with singe colony of S. cerevisiae strain (Mav203) overnight at
30oC in a shaking incubator (200-350 rpm). OD600 of overnight culture was determined,
which should be between 3.0 and 5.0. Cells were then diluted to an OD600 of 0.2 – 0.4 in
a total volume of 10 ml of YPD. Grow cells in shaking incubator until OD600 0.6 – 1.0,
this should take between 3 and 6 hours. Cells were centrifuged at room temperature for 5
minutes and 500 rpm, supernatant was discarded. Resuspend pellet in 10 ml of solution 1.
Cells were centrifuged at room temperature for 5 minutes and 500 rpm, the supernatant
was discarded. Celled were resuspended in 1 ml of solution 2. Cells were competent and
could be used immediately or frozen in 50 µl aliquots.

Transformation of Competent Cells
For each transformation one aliquot of 50 µl of competent cells was thawed. 1 µg
of vector DNA Ufd2a and VCP/p97 (see graph) (no more then 5 µl each) to competent
cells was added to aliquot. 500 µl of Solution 3 (Invitrogen S.c. EasyComp
Transformation Kit) was then added to each tube and mixed. Reaction was incubated at
30oC for 1 hour. Every 15 minutes aliquots were shaken to mix contents for superior
transformation efficiency. 150 µl of reaction was plated on -leu/-trp deficient 1.5% agar
plates.
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Bait Vector
pDEST32Ufd2a
pDEST32Ufd2aIII
pDEST32Ufd2a
pDEST32Ufd2a
pDEST32Ufd2a
empty
pDEST32
empty
pDEST33
empty
pDEST34

Prey Vector
empty pDEST22
empty pDEST23
pDEST22-VCP WT
pDEST22-VCP
R155H
pDEST22-VCP
A232E
pDEST22-VCP WT
pDEST22-VCP
R155H
pDEST22-VCP
A232E

Histidine Synthase Growth Assays
Liquid Growth Assay
4 ml of –leu/-trp/-his liquid sterile media was added to a 15 ml conical tube. With a
sterile pipette tip, touch a colony and place the tip into a tube. Tube was placed in shaker
overnight at 30oC to an OD600 of between 2.0 and 3.0. Culture was diluted down to OD600
of 1.0. In a five 96-well plate serial dilutions of in a 1:5, 1:50, 1:500, 1:5000, 1:50000
ratio in –leu/-trp media 10 mM 3-amino- 1,2,4-triazole (3AT) sterile liquid media, 25
mM 3AT liquid sterile media, 50 mM 3AT liquid sterile media, 100 mM 3AT liquid
sterile media in triplicates. This is a quantitative assay that can be read with an ELISA
reader at 600 nm.

Plate Growth Assay
4 ml of –leu/-trp/-his liquid sterile media was added to a 15 ml conical tube. Touch the tip
of sterile pipette into yeast colony. Place into conical tube. Grow overnight at 30oC to an
OD600 of between 2.0 and 3.0. Culture was diluted to an OD600 of 1.0. In a 96-well plate
the cultures were serial diluted in a 1:5, 1:50, 1:500, 1:5000, 1:50000 ratio of culture to
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media. Using a frogger replicate the 96-well plate onto a –leu/-trp plate (control plate), 10
mM 3AT, 25 mM (3AT), 50 mM 3AT, and 100 mM 3AT. Plates were incubated for 2-4
days.

Liquid β-Galactosidase Assay
4 ml of –leu/-trp media was added to 15 ml conical tubes and shaken at 30oC overnight at
200 rpm. Take the OD600. The culture was diluted to an OD600 of 0.3 in 4 ml of fresh
–leu/-trp media and shook at 30oC until OD600 of 1.0-1.5 (this should take approximately
4.0-4.5 hours). Aliquots were centrifuged, 3 ml of culture in 1.5 ml microcentrifuge tube
(12000 x g) for 30 seconds and the supernatant was discarded. 500 µl Z Buffer was added
to wash cells. Cells were resuspended in 300 µl of Z Buffer and then disrupted by adding
0.150 g of acid washed glass beads and mixing with a Vortex mixer for 30-45 minutes.
Beads settled to the bottom of the tube and liquid fraction was pipetted off and added to
350 µl Z Buffer, 0.9 µl of β-2-mercaptoethanol, 80 µl of 4mg/ml ONPG in Z Buffer.
Reaction was incubated at 30oC for 14 hours and 15 minutes. Reactions were stopped by
the addition of 400 µl of Na2CO3. Tubed were centrifuged at 12000 x g for 5 minutes.
Supernatants were collected and pipetted 200 µl into a 96-well plate in triplicates. Plate
was read at 420 nm. The β-Galactosidase activity is calculated by the equation 1000 x
A420 nm / (t x V x A600 nm). Where t = time and v = volume of culture in ml.

Chapter I: UFD2a vs UFD2a III interaction with VCP/p97
Introduction:
Ufd2a has three different isoforms in muscle cells. There is a different isoform
present in the cells depending on the stage of development. In myoblasts or precursor
muscle cells Ufd2a is present. It is the shortest isoform containing exons one through six
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and eight through twentyseven. The second isoform,
Ufd2aII is present in
differentiated muscle cells
that have not begun to fuse
together. This isoform had
exons one through seven and
eight through twenty-seven.
The third isoform is found in multinucleated, striated muscle cells. It includes exons one
through seven, seven ‘a’, and eight through twenty-seven. There have been implications
through other research that Ufd2a interacts with VCP/p97 (Paul Taylor personal
communication). However, there is no information as to the binding of VCP/p97 to either
of the other isoforms. This experiment looks at the binding affinities of Udf2a and
Ufd2aIII with VCP/p97.

Results:
The Yeast 2 Hybrid (Y2H) system works with the Gal4 promoter. The Gal4
promoter has a DNA binding domain (DBD) and an activation domain (AD) that in a
Wild Type promoter facilitates the transcription of the gene downstream from the
promoter. It was found that the binding domain and activation domain could be
separated. The DBD and AD are then fused to potential proteins that may interact with
each other. If the two proteins interact with each other, the DBD and AD are now in
proximity to each other and can drive the transcription of the reporter system.
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The vectors used for the Y2H system are pDEST32 and pDEST22 (Invitrogen).
These two vectors are built specifically for the Y2H system. These vectors are
transformed into E. coli cells and Mav203 yeast cells. To be able to select colonies in
E. coli there are antibiotic resistance genes gentamicin and ampicillin respectively. To
select colonies in yeast the two vectors together have tryptophan synthase (trp 1) and
leucine synthase (leu 2). The two vectors are transformed yeast cells and they are then
selected for on –leu/-trp deficiency media. The cells that have both vectors are then
subjected to a multitude of tests to observe if an interaction is present.

Histidine Synthase Assays
There are two histidine synthase reactions. The plate assay is a qualitative assay
that generates a visual result. The plates can then be viewed and a general idea of the
strength of reaction between the two proteins can be observed. The histidine synthase
reaction works with an antagonist, 3-amino-1, 2, 4-triazole (3AT). 3AT impairs the
production of histidine. When placed on an agar plate that has –leu/-trp/-his deficiency
media and a molar quantity of 3AT either 10 mM, 25 mM, 50 mM, or 100 mM the
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gradient of 3AT impedes the synthesis of histidine in a concentration-dependent manner.
If a bait and prey protein pair
grows on the higher concentrations
then it can be said to have a strong
binding affinity. If the protein pair
only grows on the lower
concentrations then it can be said
to have a weaker binding affinity.
Figure 3 shows Ufd2a binding with VCP/p97 in such an assay, however in the same
assay Ufd2aIII does not bind with VCP/p97. Figure 4 shows a quantitative histidine
synthase liquid assay where significant binding occurs between Ufd2a and VCP/p97 (p =
0.008). The binding of Ufd2aIII and VCP/p97 corroborates the liquid assay in that
Ufd2aIII does not bind to VCP/p97.

β-Galactisodase Liquid Assay
The liquid β-Galactisodase assay is a liquid color changing assay. The aqueous
solution changes from a clear color to a distinct bright yellow color when the
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β-Galactosidase cleaves its
substrate. The variation in
color allows the assay to be a
quantitative assay read at 420
nm. The equation
(1000xA420)/ (t x V x A600)
allows the assay to give a βGalactisodase unit which shows the activity of the binding proteins (where t is time and v
is volume of culture). This assay also corroborates both histidine synthase assays in that
there was no binding between Ufd2aIII and VCP/p97 but there was significant binding
between Ufd2a and VCP/ p97.
Conclusions:
The histidine synthase asssays along with the β-Galactisodase assay yielded
consistent results with regard to the binding affinity of Ufd2aIII and VCP/p97. There was
no significant binding between the two proteins in either of the assays. Converesely,
Ufd2a and VCP/p97 do have a significant binding affinity. This observation leads to the
next question: is the binding affinity of Ufd2a affected by mutations in VCP/p97.

Chapter 2: UFD2a interaction with VCP/p97 mutants
Introduction:
Inclusion body myopathy in association with Paget’s disease of the bone and
frontotemperal dementia (IBMPFD) is a progressive, autosomal dominant disorder that is
caused by mutations in VCP/p97 including R155H and A232E. Particular mutations in
VCP/p97 such as A232E can exhibit a stronger phenotypic expression of IBMPFD.
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These mutations occur in the C-domain of VCP/p97 as seen in the blue central unit in
figure 6 (Ju and Weihl, 2010).
R155H and A232E are two point
mutations that change one animo
acid in the protein. R155H is
originally an arginine that
changes to a histidine at amino
acid number 155. Similarly,
A232E was originally an alanine
which changed to a glutamic acid
at amino acid number 232.
Results:
Histidine Synthase Assays
The histidine synthase plate assay was employed to visualize if there a stronger binding
affinity for VCP/p97 Wild Type or if Ufd2a bound stronger to one of the mutant forms
(R155H or A232E) used in these experiments. In this assay it appears that there was
binding between Ufd2a and all three VCP/p97 forms, but that the strength of binding
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differed between the three forms of VCP/p97. VCP/p97 A232E had the strongest binding
affinity for Ufd2a. The next strongest binding affinity was with VCP/p97 R155H and the
weakest affinity was with VCP/p97 Wild Type (Figure 7). The liquid histidine synthase
assay corroborates the plate assay with a p < 0.001 (Figure 8).

β-Galactosidase Assay
The β-Galactosidase assay is not as sensitive as the histidine synthase assay. It can only
be used to determine if
there is a strong reaction.
The assay showed that
there was a significant
binding affinity between
Ufd2a and VCP/p97
A232E. There was no
significant binding in this
assay between the other two forms of VCP/p97 (Wild Type or R155H) the p < 0.001.
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Conclusions:
In this set of assays it is clear that there are differences in the binding affinities of
Ufd2a and the three forms of VCP/p97. The histidine synthase assays show that there are
differences between the three different forms of VCP/p97 and the control groups but that
there is also a difference in the binding affinities of VCP/p97 Wild Type, R155H, and
A232E. With the corroboration of the B-Galactosidase assay it is clear that VCP/p97
A232E has the strongest binding affinity.

Overall Conclusions:
Consistent results showed that there was not binding between Ufd2aIII and
VCP/p97. How ever there was significant binding between Ufd2a and VCP/p97. This
significance was thought to occur when the experiment began and this confirmed the
suspicion that these two proteins interacted with each other in the proteosome pathway.
When looking at the comparison of Ufd2a and VCP/p97 Wild Type, R155H, and A232E
there was a significant difference in the binding affinities not just between the controls
and the three forms of VCP/p97 individually.

Discussion:
Ufd2a has a multitude of functions. It adds ubuquitin to specific substrates, it adds
chains of ubiquitin to specific substrates, it works in the proteosome degradation
pathway, it may work with autophagy, and it also binds to VCP/p97 where it affects the
disease inclusion body myopathy in association of Paget’s disease of the bone and
frontotemperal dementia.
Ufd2aIII does not bind to VCP/p97. This is thought to be an exclusive binding
partner. Therefore in mature, multinucleated, striated muscle cells VCP/p97 is able to
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bind to other cofactors. The binding of VCP/p97 to these other cofactors might be what
are affecting the people that have IBMPFD.
Ufd2a had a strong binding affinity for VCP/p97 A232E and R155H. These
specific mutations give a stronger phenotypic manifestation of the disease and now it can
be linked to a stronger binding affinity to Udf2a. Perhaps the reason for this stronger
phenotypic manifestation is because Ufd2a is binding so tightly that it is not releasing
VCP/p97 so that it can work with its other binding partners. It has been determined that a
deficiency of VCP/p97 by knockdown or over expression of dominant negative VCP/p97
results in a significant accumulation of immature autophagic vesicles; some are
abnormally large, others acidified and exhibit cathepsin B activity. However, the disease
mutants R155H and A232E also cause this defect in autophagic vesicles (Tresse and
Taylor et al, 2010). These autophagic vesicles are part of the IBMPFD disease.
Further research will be conducted to see if Ufd2aIII has a significant binding
affinity for any of the VCP/p97 mutants.

23

Acknowledgements
I would like to thank Dr. Paul Taylor and Brett Winborn (St.Jude’s Children’s Hospital,
KE) for supplying the three VCP entry vectors. A special thank you to Dr. Eric Roberts
(RIC) for his essential assistance in the piloting of the Yeast2Hybrid system to the
students of the BIO 553 (Spring 2010 Semester) for their work in the construction of
pENTR-Ufd2aI and the pDEST22-VCP/p97 (WT, R155H, and A232E). I would also
like to thank Brenda Cordiero (RIC) for the use of Ufd2aIII in pDEST201 vector. Dr.
Thomas Meedel (RIC) for his valuable input on the creation of this manuscript. Funding
for this project was provided by RI-INBRE grant# 20RR016457 from the National Center
for Research Sources (NCRR), a component of the National Institute of Health (NIH).
Sequencing was conducted using the Rhode Island Genomics and Sequencing Center
which is supported in part by the National Science Foundation (MRI Grant No.DBI0215393 and EPSCoR Grant No.0554548), the US Department of Agriculture (Grant
Nos. 2002-34438-19246,2003-34438-13111, and 2008-34438-19246) and the University
of Rhode Island.

References:
Ju J.S.; Weihl C. Inclusion body myopathy, Paget’s disease of the bone and frontotemporal dementia: a disorder of autophagy. H Mol Gen. 2010 19(R1) R38–R45
Kaneko C, Hatakeyama S, Matsumoto M, Yada M, Nakayama K, Nakayama KI.
Characterization of the mouse gene for the U-box-type ubiquitin ligase UFD2a.
Biochem.Biophys.Res.Commun. 2003 Jan 10;300(2):297-304.
Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel
ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999 Mar
5;96(5):635-44.
Mahoney JA, Odin JA, White SM, Shaffer D, Koff A, Casciola-Rosen L, Rosen A. The
human homologue of the yeast polyubiquitination factor Ufd2p is cleaved by caspase 6
and granzyme B during apoptosis. Biochem.J. 2002 Feb 1;361(Pt 3):587-95.
Emilie Tresse, Florian A. Salomons, Jouni Vesa, Laura C. Bott, Virginia Kimonis,TsoPang Yao, Nico P. Dantuma, and J. Paul Taylor. VCP/p97 is essential for maturation of
ubiquitin-containing autophagosomes and this function is impaired by mutations that
cause IBMPFD. Autophagy 2010 Feb 6:2, 217-227

24

